PDSBPDS Biotechnology Corp.Finished
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
Metastatic Head and Neck Cancer · Recurrent Head and Neck Cancer · HPV Positive Oropharyngeal Squamous Cell Carcinoma · Neoplasms, Head and Neck
16Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due May 2025, none posted yet
Counts until it's fixed
- +6.5
Announced layoffs or restructuring
Since Aug 25, 2026 · was worth 15, fading over time
Worry score17 (capped at 16)
Score over time
- Stage
- Phase 2
- Patients
- 95 (final count)
- Started
- Mar 29, 2021
- Main results expected
- May 14, 2025
- Fully finished
- May 14, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Best Overall Response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) of the combination of pembrolizumab and PDS0101.
Measured over: 24 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-05-14, no fading
- layoffs: base 15, now 6.5, since 2026-08-25, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT04260126 · record last updated 2025-10-01 · checked 2026-11-09 06:30 UTC